NCT01489670View on ClinicalTrials.gov

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

CompletedOBSERVATIONAL
Enrollment

387

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

bimatoprost 0.01% ophthalmic solution

Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.

Trial Locations (1)

Unknown

Bülach

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01489670 - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter